Investor profile

CD3 II (Centre for Drug Design and Discovery)

KU Leuven Research & Development · Belgium

EIF

Investment focus

Start with the fit.

CD3 II is a life-science fund run by the Centre for Drug Design and Discovery, the drug-discovery investment vehicle set up by KU Leuven Research & Development in Leuven, Belgium. It invests in early drug-discovery projects, academic spin-offs and biotechs across Europe, pairing capital with an in-house drug-discovery team. It is backed by the European Investment Fund alongside KU Leuven.

Reported portfolio

Companies in the record.

30+ drug discovery projects and biotech spinoffs across virology, oncology, CNS, and auto-immune research

AI Connector · MCP

Bring EUACC into your AI.

Choose your AI and follow the walkthrough. Your free EUACC account connects the two.

Illustrated walkthrough

Add EUACC to Claude

In Claude, open Customize, then Connectors.
Click + Add, then Add custom connector.
Name it EUACC, paste the link and click Continue.
Review the detected authentication settings and click Continue. Choose Sign in now, then Register automatically under OAuth client.
Click Add, then sign in with your free EUACC account and approve access.

Connector URLhttps://www.euacc.ai/api/mcp

Works on every Claude plan, including Free (one custom connector). On Team and Enterprise, an Owner adds it.

On a phone, add it at claude.ai in your browser. It then shows up in the Claude app the next time you sign in.

Once connected, try this

Use EUACC to explore “Cd3 ii centre for drug design and discovery” (https://www.euacc.ai/investors/cd3-ii-centre-for-drug-design-and-discovery). Help me assess investor fit and prepare questions using the available fund profiles. Cite the available sources and flag missing or outdated information.

Your side of the introduction

Give investors a profile worth opening.

List your startup →

Start with the fit.